%A Chen,Qi %A Zhao,Min %A Yin,Chengliang %A Feng,Shiyu %A Hu,Jian %A Zhang,Qiang %A Ma,Xiaodong %A Xue,Wanguo %A Shi,Jinlong %D 2019 %J Frontiers in Neuroscience %C %F %G English %K Glioblastoma,biomarker,Methylation,Prognostic evaluation,joint-score %Q %R 10.3389/fnins.2019.01137 %W %L %M %P %7 %8 2019-October-25 %9 Original Research %# %! Methylation signals Predicting GBM Prognosis %* %< %T Hypomethylation of 111 Probes Predicts Poor Prognosis for Glioblastoma %U https://www.frontiersin.org/articles/10.3389/fnins.2019.01137 %V 13 %0 JOURNAL ARTICLE %@ 1662-453X %X Glioblastoma (GBM) is a complicated brain tumor with heterogeneous outcome. Identification of effective biomarkers is an urgent need for the treatment decision-making and precise evaluation of prognosis. Based on a relatively large dataset of genome-wide methylation (138 glioblastoma patients), a joint-score of 111 methyl-probes was found to be of statistical significance for prognostic evaluation. Low joint-score were significantly associated with adverse outcomes (OS: P < 0.001, PFS: P = 0.03). Multivariable analyses adjusted for known risk factors confirmed the low joint-score of 111 methyl-probes as a high risk factor. The prognostic value of the methylated joint-score was further validated in another dataset of glioblastoma patients (OS: P = 0.006). Additionally, variance analysis revealed that aberrant genetic and epigenetic alterations were significantly associated with the joint-score of those methyl-probes. In conclusion, our results supported the joint-score of 111 methyl-probes as a potential prognosticator for the precision treatment of glioblastoma.